Our long-term recovery from COVID-19 depends not on a vaccine, but our developing global herd immunity. This is because third world countries are unlikely to be able to administer regular mass re-vaccinations. Therefore, it is good to know almost everyone who contracts the disease develops antibodies. Moreover, measuring their presence could be a vital clue to the extent of US COVID-19.
China Study Confirms Vital Clue to the Extent of COVID-19
National Institutes of Health Director’s Blog says nearly everybody who recovers from COVID-19, makes coronavirus antibodies. Furthermore, they underpin this with reference to two China studies. In the first, researchers studied blood samples from 285 people with severe COVID-19. All developed antibodies within two weeks.
While in a second group of admissions, all 65 people admitted, and tested every three days developed specific antibodies within twenty days. Of course, one could argue this was not a randomized sample. But it could be a vital clue to the extent of US COVID-19, in our search for safe, effective, sustained protection.
Less Than 10% of Americans Had Antibodies by July 2020
The second study reported in National Institutes of Health Director’s Blog is closer to home. This relates to an articled in The Lancet of September 25, 2020. It found less than 10% of the U.S. adult population formed antibodies against SARS-CoV-2 through July 2020. And moreover, fewer than 10% of those with antibodies were diagnosed.
However, this study is also far from random because all the subjects were receiving dialysis treatment for kidney failure. But this time the sample was taken from 28,503 tests, supplied by approximately 1,300 dialysis facilities. This therefore could be a vital clue to the extent of US COVID-19 in North America, as things stood at that time.
Related
Antibodies Decay Quickly In Small Study
U.S. Clinical Trials of Monoclonal Antibodies
Preview Image: An Antibody Test Kit
Antibody Responses to SARS-CoV-2
Study Reported in The Lancet Journal
